Journal of Endocrinological Investigation

, Volume 31, Issue 3, pp 251–254 | Cite as

Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity — Observations in two elderly patients

Original Articles


Alendronate is a potent aminobisphosphonate that has been used worldwide to decrease fracture risk in millions of post-menopausal women with and without osteoporosis, men with low bone mass, and in those with glucocorticoid-induced osteoporosis. A recent report of 9 patients with spontaneous atypical non-vertebral fractures during treatment with alendronate for up to 8 yr raised questions suggesting the possibility of severe suppression of bone turnover and resultant susceptibility to fracture. Our recent observations in 2 elderly women with inactive monostotic Paget’s disease of bone who had been treated elsewhere continuously for this disease with alendronate for 10 yr at doses overall of 2 and 4 times the osteoporotic dose provided an opportunity to engage in the ongoing controversy over long-term safety of bisphosphonate therapy. Despite such therapy, skeletal integrity was maintained with normal bone densities and the absence of skeletal fractures. These observations do not support the suggestion of deleterious effects with long-term alendronate therapy.


Alendronate osteoporosis fractures Paget’s disease bone turnover 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333: 1437–43.Google Scholar
  2. 2.
    McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998, 128: 253–61.Google Scholar
  3. 3.
    Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348: 1535–41.Google Scholar
  4. 4.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280: 2077–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate forthe prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339: 292–9.Google Scholar
  6. 6.
    Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. New Engl J Med 2000, 343: 604–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate forthe treatment of Paget’s disease of bone. J Clin Endocrinol Metab 1996, 81: 961–7.PubMedGoogle Scholar
  8. 8.
    Bone HG, Downs RW Jr, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 1997, 82: 265–74.Google Scholar
  9. 9.
    Weinstein RS. True strength. J Bone Miner Res 2000, 15: 621–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Ott SM. Fracture after long-term alendronate therapy. J Clin Endocrinol Metab 2001, 86: 1835–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90: 1294–301.PubMedCrossRefGoogle Scholar
  12. 12.
    Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005, 90: 1897–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85: 3109–15.Google Scholar
  14. 14.
    Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during anteresorptive therapy. Mayo Clin Proc 2005, 80: 379–88.PubMedCrossRefGoogle Scholar
  15. 15.
    Balena R, Markatos A, Guy J, et al. Effect of three years treatment with alendronate in adult beagles. J Bone Miner Res 1993, 8: S270 (abstract).Google Scholar
  16. 16.
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15: 613–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Ding M, Day JS, Burr DB, et al. Canine cancellous bone architecture after one year of high-dose bisphosphonates. Calcif Tissue Int 2003, 72: 737–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Burr D. Microdamage and bone strength. Osteoporosis Int 2003, 14(Suppl 5): 67–72.CrossRefGoogle Scholar
  19. 19.
    Mori S, Harruff R, Ambrosius W, Burr DB. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 1997, 21: 521–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100: 1475–80.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27: 687–94.PubMedCrossRefGoogle Scholar
  22. 22.
    Boivin GY, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002, 43: 535–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Bone HG, Hosking D, Devogelaer J, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350: 1189–99.PubMedCrossRefGoogle Scholar
  24. 24.
    Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-Term extension. J Bone Miner Res 2004, 19: 1259–69.PubMedCrossRefGoogle Scholar
  25. 25.
    Recker R, Ensrud K, Diem S, et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res 2004, 19: S45 (abstract).CrossRefGoogle Scholar
  26. 26.
    Deftos LJ. Treatment of Paget’s disease—taming the wild osteoclast. N Engl J Med 2005, 353: 872–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Vellenga CJ, Pauwels EK, Bijvoet OL, Harinck HI, Frijlink WB. Quantitative bone scintigraphy in Paget’s disease treated with APD. Br J Radiol 1985, 58: 1165–72.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2008

Authors and Affiliations

  1. 1.Department of MedicineRoger Williams Medical CenterProvidence
  2. 2.Boston University School of MedicineBoston
  3. 3.Brown University Medical SchoolProvidenceUSA
  4. 4.ProvidenceUSA

Personalised recommendations